Our Research
Discover our recent findings, catch up with news, and review in-depth resources.
Case Studies
One Picogram Per Millilitre: Quantifying Free MMAE in Human Plasma for ADC Clinical Studies
Resolian developed and validated an MSD-based bridging ECLIA method for analysing anti-drug antibodies against a GalNAc-conjugated siRNA therapeutic, evaluating both MSD and Gyrolab platforms for different GalNAc-conjugated siRNA therapeutics and providing a practical framework for immunogenicity assay development in this novel modality.
Blog
Bioanalytical Partner for Biopharma Startups: 5 Proven Selection Criteria
Choosing a bioanalytical partner for biopharma startups? Follow these 5 proven criteria to protect your timeline, data quality, and regulatory readiness.
Case Studies
From a Butterfly Wing to Nanoscale Structure: What Correlative Microscopy Reveals
See how Resolian pairs light microscopy and SEM to reveal structure from macro view to nanoscale, and what this means for your next investigation.
Blog
7 Proven Steps to Choosing a Bioanalytical CRO for Global Drug Development
Running a global program? Here’s how to choose a bioanalytical CRO for global drug development, from lab footprint to phase-to-phase handoffs.
Case Studies
Leaner, More Reliable: Building a Fit-for-Purpose LC-MS System Suitability Mixture for Extractables and Leachables Screening
Resolian’s Analytical Sciences team developed a simplified, USP-aligned system suitability test mixture for non-targeted LC-HRAMS extractables and leachables screening, reducing component count from fifteen to fewer than ten while maintaining coverage of all key USP stimulus attributes.
Case Studies
Immunogenicity in the Age of siRNA: Developing ADA Assays for GalNAc-Conjugated siRNA Therapeutics
Resolian developed and validated an MSD-based bridging ECLIA method for analysing anti-drug antibodies against a GalNAc-conjugated siRNA therapeutic, evaluating both MSD and Gyrolab platforms for different GalNAc-conjugated siRNA therapeutics and providing a practical framework for immunogenicity assay development in this novel modality.
